FCR vs. BR - Is One Better? episode artwork

EPISODE · Aug 26, 2016 · 4 MIN

FCR vs. BR - Is One Better?

from GRACEcast · host cancerGRACE Meetings

Jennifer Brown, MD, discusses the choice in chemoimmunotherapy, FCR (fludarabine, cyclophosphamide and rituximab) vs BR. FCR has been the standard therapy for previously untreated fit patients with CLL under about the age of 70. While BR (bendamustine and rituximab), is a relatively newer therapy, which had been studied in a couple of phase two trials - smaller single arm trials and look to be promising.

Episode metadata supplied by the publisher feed · Published Aug 26, 2016

Embed this episode

NOW PLAYING

FCR vs. BR - Is One Better?

0:00 4:23

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 4 minutes long.

When was this GRACEcast episode published?

This episode was published on August 26, 2016.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!